Clinical trial
Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain
Abstract
This study is to assess the efficacy and safety of a four-week treatment with intranasal esketamine (56 mg) twice a week combined with opioid analgesic and adjuvant standard therapy in the management of adult patients with severe and opioid refractory chronic cancer pain.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticleKetamine
Ketamine for Cancer-Related Pain in Palliative Care: A Systematic Review of Clinical Use and Safety.
ArticleKetamine
Efficacy and safety comparison of esketamine-propofol with nalbuphine-propofol for upper gastrointestinal endoscopy in children: a multi-center randomized controlled trial.
ArticleKetamine